-
公开(公告)号：US20250064787A1
公开(公告)日：2025-02-27
申请号：US18933481
申请日：2024-10-31
Applicant: Lilac Therapeutics, Inc.
Inventor： Hongyan Guo , Amy S. Lee , Hyung-Jung Pyun , Devleena M. Shivakumar , Manoj C. Desai , Lianhong Xu , John E. Knox , Zachary ER Newby
IPC: A61K31/4192 , A61K31/19 , A61K31/194 , A61K31/351 , A61K31/381 , A61K31/382 , A61K31/415 , A61K31/4164 , A61K31/422 , A61K31/427 , A61K31/428 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/675 , A61K31/7048 , A61K38/51 , A61K45/06 , C07D231/14 , C07D233/90 , C07D249/06 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/10 , C07D405/14 , C07D413/10 , C07D417/04 , C07D417/10 , C07F9/6558 , C12N15/113
Abstract: The present disclosure relates to compounds, compositions, and methods for the treatment of primary hyperoxaluria type 1 and recurrent kidney stone formers. The present disclosure is directed to novel substituted heterocyclic carboxylate compounds and methods for their preparation and use as therapeutic or prophylactic agents. In particular, the present disclosure provides novel inhibitors of human glycolate oxidase enzyme, pharmaceutical compositions containing such compounds, and methods for using these compounds to treat primary hyperoxaluria type 1 and recurrent kidney stone formers.
-
公开(公告)号：US12233059B2
公开(公告)日：2025-02-25
申请号：US18670637
申请日：2024-05-21
Applicant: Alto Neuroscience, Inc.
Inventor： Amit Etkin , Wei Wu , Chao Wang , Nicholas Cooper , Joshua Jordan , Adam Savitz
Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.
-
3.发明申请
公开(公告)号：US20250057792A1
公开(公告)日：2025-02-20
申请号：US18936779
申请日：2024-11-04
Applicant: Metabolic Technologies, LLC
Inventor： John Rathmacher , Naji Abumrad , Shawn Baier
IPC: A61K31/19
Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance or promote lipolysis, increase adipocyte fat oxidation, induce adipocyte and muscle mitochondrial biogenesis, increase energy expenditure, decrease total body weight and increase body fat loss.
-
公开(公告)号：US12226389B2
公开(公告)日：2025-02-18
申请号：US18759364
申请日：2024-06-28
Applicant: Flamel Ireland Limited
Inventor： Claire Mégret , Hervé Guillard , Jean-François Dubuisson
Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
-
公开(公告)号：US12226377B2
公开(公告)日：2025-02-18
申请号：US17837740
申请日：2022-06-10
Applicant: Flamel Ireland Limited
Inventor： Julien Grassot , Cendrine Grangeon , Jordan Dubow
Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
-
公开(公告)号：US20250049745A1
公开(公告)日：2025-02-13
申请号：US18721141
申请日：2022-12-22
Applicant: NUTRITION SCIENCES N.V.
Inventor： Geert BRUGGEMAN
Abstract: The current invention relates to compositions comprising a short and medium-chain fatty acids (SCFA-MCFAs) fraction to be used in food or feed applications.
-
公开(公告)号：US12220429B2
公开(公告)日：2025-02-11
申请号：US15267220
申请日：2016-09-16
Applicant: WIAB Water Innovation AB
Inventor： Geir Hermod Almås
Abstract: The invention provides a skin disinfectant for treating skin with eczema, preventing bacterial proliferation, and removing biofilm. Compositions of the invention include hypochlorous acid, acetic acid, water, and one or more additives or excipients. The formulation process removes metal ions, reduces ionic strength, controls pH, and reduces exposure to air, thus improving stability and lengthening shelf-life.
-
公开(公告)号：US20250017950A1
公开(公告)日：2025-01-16
申请号：US18710471
申请日：2022-11-16
Applicant: UCL BUSINESS LTD , UNITED KINGDOM RESEARCH AND INNOVATION
Inventor： Antonella Spinazzola , Ian Holt , Boris Pantic , Daniel Ives
IPC: A61K31/7004 , A61K31/19 , A61K31/70 , A61K38/50
Abstract: There is described a compound for use in the treatment of a mitochondrial DNA disorder, wherein the compound is a glycolysis inhibitor, an inhibitor of glutamine consumption or is L-asparaginase or pegaspargase. The glycolysis inhibitor may be a glucose analogue such as 2-deoxy-D-glucose (2DG) or 5-thioglucose (5TG). Also described is a method of treating a mitochondrial DNA disorder comprising administering a therapeutically effective amount of the compound above to a patient suffering from a mitochondrial DNA disorder. In addition, there is described a method of reducing the mtDNA heteroplasmy in the cells of a patient comprising administering a therapeutically effective amount of the compound above to the patient.
-
9.发明申请
公开(公告)号：US20250017883A1
公开(公告)日：2025-01-16
申请号：US18901917
申请日：2024-09-30
Inventor： Alla ARZUMANYAN , Ira C. Spector , Mark A. Feitelson
Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.
-
公开(公告)号：US20250017882A1
公开(公告)日：2025-01-16
申请号：US18898132
申请日：2024-09-26
Applicant: Flamel Ireland Limited
Inventor： Julien Grassot , Cendrine Grangeon , Jordan Dubow
Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
